Miller Christopher B, Kyle Simon D, Gordon Christopher J, Espie Colin A, Grunstein Ronald R, Mullins Anna E, Postnova Svetlana, Bartlett Delwyn J
Centre for Integrated Research and Understanding of Sleep (CIRUS), NeuroSleep and Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.
Sleep & Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom.
PLoS One. 2015 Dec 18;10(12):e0145317. doi: 10.1371/journal.pone.0145317. eCollection 2015.
The aim of this preliminary study was to evaluate if Sleep Restriction Therapy for insomnia is associated with modifications to physiological arousal, indexed through overnight measures of plasma cortisol concentrations and core body temperature.
In a pre-to-post open label study design, eleven patients with chronic and severe Psychophysiological Insomnia underwent 5 weeks of Sleep Restriction Therapy.
Eight (73%) patients out of 11 consented completed therapy and showed a decrease in insomnia severity pre-to-post treatment (mean (SD): 18.1 (2.8) versus 8.4 (4.8); p = .001). Six patients were analyzed with pre-to-post overnight measures of temperature and cortisol. Contrary to our hypothesis, significantly higher levels of plasma cortisol concentrations were found during the early morning at post-treatment compared to baseline (p < .01), while no change was observed in the pre-sleep phase or early part of the night. Core body temperature during sleep was however reduced significantly (overall mean [95% CI]: 36.54 (°C) [36.3, 36.8] versus 36.45 [36.2, 36.7]; p < .05).
Sleep Restriction Therapy therefore was associated with increased early morning cortisol concentrations and decreased core body temperature, supporting the premise of physiological changes in functioning after effective therapy. Future work should evaluate change in physiological variables associated with clinical treatment response.
Australian New Zealand Clinical Trials Registry ANZCTR 12612000049875.
本初步研究旨在评估失眠的睡眠限制疗法是否与生理觉醒的改变相关,通过夜间血浆皮质醇浓度和核心体温测量来衡量。
在一项前后开放标签研究设计中,11名患有慢性重度心理生理性失眠的患者接受了5周的睡眠限制疗法。
11名同意参与的患者中有8名(73%)完成了治疗,治疗前后失眠严重程度有所降低(均值(标准差):18.1(2.8)对8.4(4.8);p = 0.001)。对6名患者进行了治疗前后夜间体温和皮质醇的测量。与我们的假设相反,治疗后清晨血浆皮质醇浓度显著高于基线水平(p < 0.01),而睡前阶段或夜间早期未观察到变化。然而,睡眠期间的核心体温显著降低(总体均值[95%置信区间]:36.54(°C)[36.3, 36.8]对36.45 [36.2, 36.7];p < 0.05)。
因此,睡眠限制疗法与清晨皮质醇浓度升高和核心体温降低相关,支持有效治疗后功能发生生理变化的前提。未来的研究应评估与临床治疗反应相关的生理变量的变化。
澳大利亚新西兰临床试验注册中心ANZCTR 12612000049875。